代谢调节:Pneumocystis的糖突变酶是一种影响宿主识别的标
Theodore J Kottom1, Eva M Carmona1, Bernd Lepenies2,3
1Thoracic Diseases Research Unit, Departments of Medicine and Biochemistry, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Cell surface (Amsterdam, Netherlands)
|July 18, 2024
概括
糖突变酶 (PGM) 对于在Pneumocystis中的真菌人蛋白形成至关重要. 抑制PGM可能提供针对真菌感染的广泛治疗策略.
科学领域:
- 生物化学 生物化学
- 菌类学 菌类学是指菌类学.
- 分子生物学分子生物学
背景情况:
- 在真菌表面的曼诺蛋白对宿主-病原体相互作用至关重要.
- 糖突变酶 (PGM) 在Pneumocystis mannoprotein合成中的作用尚不清楚.
研究的目的:
- 为了研究酸葡萄糖突变酶 (PGM) 在Pneumocystis spp.中的功能.
- 探索PGM在真菌细胞壁中产生曼蛋白的作用.
- 评估PGM作为治疗点的潜力.
主要方法:
- 在Saccharomyces cerevisiae pgm2Δ突变菌株中表达Pneumocystis murina Pmpgm2基因.
- 评估曼诺糖受体 (MR) 结合和巨细胞相互作用.
- 使用气体染色学-质谱学 (GC-MS) 来量化曼含量.
主要成果:
- 补充S. cerevisiae pgm2Δ菌株与Pmpgm2恢复的MR和巨细胞结合到野生类型水平.
- GC-MS分析显示,在pgm2Δ酵母菌株中,曼诺含量有所降低.
- 这项研究强调了PGM在多利科尔葡萄糖酸盐生物合成中对细胞壁完整性的作用.
结论:
- 菌PGM对于适当的曼诺蛋白形成和细胞壁生物合成至关重要.
- 通过真菌病原体在PGM中保存的可向的半氨酸残留物表明了广泛的治疗策略的潜力.
- 抑制PGM为开发新的抗真菌治疗提供了一个有希望的途径.
相关概念视频
01:19Regulation of Metabolism
9.1K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.1K
01:29Pneumonia II: Pathophysiology
4.7K
The pathophysiology of pneumonia involves the following steps:
4.7K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:27Cytomegalovirus Disease
102
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
102